Please enjoy this transcript of my interview with Adam Gazzaley (@adamgazz), the David Dolby Distinguished Professor of Neurology, Physiology, and Psychiatry at the University of California, San Francisco, and the founder and executive director of Neuroscape, a translational neuroscience center engaged in technology development and scientific research of novel brain assessments and optimization tools. Adam is co-founder and chief science advisor of Akili Interactive, Sensync, and JAZZ Venture Partners. He has been a scientific adviser for more than a dozen technology companies, including Apple, GE, Nielsen, and Deloitte.
Adam has filed multiple patents—notably his invention of the first video game cleared by the FDA—authored more than 150 scientific articles, and delivered over 675 invited presentations around the world. He wrote and hosted the nationally televised PBS special The Distracted Mind with Dr. Adam Gazzaley and co-authored The Distracted Mind: Ancient Brains in a High-Tech World, winner of the 2017 PROSE Award. Adam has received many awards and honors, including the 2015 Society for Neuroscience Science Educator Award and the 2020 Global Gaming Citizen honor.
Visit this page to learn more about the Neuroscape Psychedelic Division, which is dedicated to advancing the field of psychedelic science and medicine through multi-level research covering basic to translational to clinical science.
Transcripts may contain a few typos. With some episodes lasting 2+ hours, it can be difficult to catch minor errors. Enjoy!
DUE TO SOME HEADACHES IN THE PAST, PLEASE NOTE LEGAL CONDITIONS:
Tim Ferriss owns the copyright in and to all content in and transcripts of The Tim Ferriss Show podcast, with all rights reserved, as well as his right of publicity.
WHAT YOU’RE WELCOME TO DO: You are welcome to share the below transcript (up to 500 words but not more) in media articles (e.g., The New York Times, LA Times, The Guardian), on your personal website, in a non-commercial article or blog post (e.g., Medium), and/or on a personal social media account for non-commercial purposes, provided that you include attribution to “The Tim Ferriss Show” and link back to the tim.blog/podcast URL. For the sake of clarity, media outlets with advertising models are permitted to use excerpts from the transcript per the above.
WHAT IS NOT ALLOWED: No one is authorized to copy any portion of the podcast content or use Tim Ferriss’ name, image or likeness for any commercial purpose or use, including without limitation inclusion in any books, e-books, book summaries or synopses, or on a commercial website or social media site (e.g., Facebook, Twitter, Instagram, etc.) that offers or promotes your or another’s products or services. For the sake of clarity, media outlets are permitted to use photos of Tim Ferriss from the media room on tim.blog or (obviously) license photos of Tim Ferriss from Getty Images, etc.
This interview was transcribed by Rev.com.
Tim Ferriss: Hello, boys and girls, ladies and germs. This is Tim Ferriss. And welcome to another episode of the Tim Ferriss Show, where it is my job to interview world-class performers from all different disciplines, all different areas to tease out habits, frameworks, lessons learned, tools that you can use, insights that you might apply to your own life, questions that might enable you in some fashion. My guest today is close friend, Adam Gazzaley, MD, PhD. You can find him on Twitter at @AdamGazz, G-A-Z-Z. Adam is the David Dolby Distinguished Professor of Neurology, Physiology, and Psychiatry at the University of California, San Francisco, and the founder and executive director of Neuroscape, a translational neuroscience center engaged in technology development and scientific research of novel brain assessments and optimization tools. Dr. Gazzaley is co-founder and chief science advisor of Akili Interactive, Sensync, and JAZZ venture partners. He has been a scientific advisor for more than a dozen technology companies, including Apple, GE, Neilson, and Deloitte. Gazzaley has filed multiple pallents.
Adam Gazzaley: Try that again.
Tim Ferriss: I might keep that one in. Also, I just never refer to you as Gazzaley. Anyway, Gazzaley, I like it. Gazzaley has filed multiple patents, notably his invention of the first video game cleared by the FDA, authored more than 150 scientific articles, and delivered over 675 invited presentations around the world. God, that makes me exhausted just reading it. He wrote and hosted the nationally televised PBS special The Distracted Mind with Dr. Adam Gazzaley and co-authored The Distracted Mind, subtitle, Ancient Brains in a High-Tech World, winner of the 2017 PROSE Award. Dr. Gazzaley has received many awards and honors, including the 2015 Science Educator Award and the 2020 Global Gaming Citizen honor. You can find him online in several places, gazzaley.com, as well as in neuroscape.ucsf.edu and on social on Facebook, Instagram, Twitter, AdamGaz, and you can also find him on LinkedIn. He is easy to find, there aren’t many Adam Gazzaleys running around. Adam, welcome back to the show.
Adam Gazzaley: Thanks so much, Tim. Excited to be here with you.
Tim Ferriss: I am excited also because you have what appears to be a professional sports center broadcasting headset. Those who are not watching video can’t see it, but I am very reassured that if this neuroscience thing doesn’t work out for you, you have a compelling plan B.
Adam Gazzaley: And it was quite a way to overdo the Zoom world that we live in now with this headset but at least for this podcast, I will be well heard. So thank you.
Tim Ferriss: And thanks to Matt Mullenweg, also, for his tech enabling. For people who did not join us in the first conversation we had on the podcast, I wanted to mention a few highlights or just a few topics that we brought up. So the first conversation we had, I didn’t realize until during prep for this conversation, because there was a summary of our previous conversation, which said Kevin and Darya Rose are moving to New York. And I thought to myself, good God, how long ago was that? And it was 2015. So in 2015 —
Adam Gazzaley: Yeah. It’s been a long —
Tim Ferriss: It’s been a long time. And your bio has developed quite a bit since. And the title of that was The Maverick of Brain Optimization. And I’ll mention a few reasons for choosing that title. And that was my choice; I don’t think you would choose that for yourself. But we discussed many things, and I want to paint a picture of some of the tools and types of development that you have explored in your time as a scientist.
And one of those is NeuroRacer, which is a piece of software that was featured on the cover of Nature and the title, as I remember it, was Game Changer. And you’ll correct me if I’m wrong, I’ll just try to summarize this really quickly, but the paper was able to show that a team of scientists could work with video game professionals to build something customized that targets processing the brain that’s deficient in a certain population. And I’m going to ask you to just give some numbers in a minute, but in this particular case it was older adults and their cognitive control abilities. So some might say the age-related cognitive decline.
And once you’ve built the software, you can construct a carefully controlled study, placebo-controlled and neural measurements to document the mechanisms of effect and show that you can create sustainable and meaningful changes in the brain using a video game. And just as a footnote, that cognitive abilities begin to decline around — or certain cognitive abilities around what? Early to mid-20s?
Adam Gazzaley: Mm-hmm (affirmative).
Tim Ferriss: That be accurate to say?
Adam Gazzaley: That’s accurate.
Tim Ferriss: So what were some of the outcomes of the study or the paper that was featured on the cover of Nature?
Adam Gazzaley: Yeah, that was really quite a game changer for me as well. Only time has told how far that technology and that research has gone and we could dive into what it’s become now. It’s fun to think back, that paper was published in 2013 and it took five years of both tech development to build that video game with friends at LucasArts, as well as to do the multiple research studies that went into that paper in Nature and why it was so exciting was that what we were able to show was that we could improve the ability of these healthy 60-plus-year-olds, not just to play the game, but their ability to sustain their attention in a very boring context, as well as their working memory, holding information in mind for short periods of time. And what we were showing is that we were really improving and their ability to multitask on the game to levels of 20-year-olds.
So it was really reversing a lot of the changes that occur with healthy aging. And we could see those changes occurring, not just in terms of their performance, but neurally because we recorded with high density EEG how they responded to these challenges before and after a month of gameplay. We could then look over time, six months later, and actually we have a paper that is just being accepted for publication now showing six years later that in these older adults, we see some benefits, not all the benefits retain over that period of time, which is really quite exciting and opens up the possibility to really push what we can do to lead to the sustainable benefits.
Tim Ferriss: What was the age range of subjects roughly, or the average?
Adam Gazzaley: They were 60 and over. I think we had one that was a 90-year-old, but mostly 60- and 70-year-olds.
Tim Ferriss: And the game, the software, as an intervention, was able to restore or revert some of their cognitive function to the level of 20-somethings?
Adam Gazzaley: Correct.
Tim Ferriss: Is that accurate?
Adam Gazzaley: Yep. That’s accurate.
Tim Ferriss: And just to restate what you said for people who might’ve missed it, please again, correct me if I’m wrong, but the durability of the effect, in other words, seeing the retention of a lot of these improvements six months later, was not because they continued to play this game on a regular basis going forward.
Adam Gazzaley: Correct. They did not play it at all, even though many of them wanted to after the one month of training. And so that’s why when we brought them back just recently, this is not published, it’ll be out soon, six years later, their ability to play that game at a much higher level than they did before was retained without any boosters. And this is not a real-world design because as this becomes a true treatment intervention that we want in the real world, and we could talk about where it’s gone, we would not think about that type of durability as the goal, it would be more reasonable to boost those effects over time with doses along the way. Just like if you were going to enhance your physical performance, your strength, your aerobic ability, you wouldn’t think oh, a month in the gym, and then I’m good until six years later.
So the fact that anything lasted is mind-boggling to me as a neuroscientist, but it’s more of a proof of concept that these circuits and these abilities when they change can be enduring, but in the real-world implementation it would make much more sense to, in a personalized way, boost these effects along the passage of time.
Tim Ferriss: For those not involved in scientific research, what would you compare being the cover of Nature to? I mean, is it comparable to winning an Oscar for best director or best picture? I mean, that’s how I’ve, in some ways, thought of it because I don’t have, perhaps, other comparables. I know you’re very self-effacing and humble when we talk and also just in general, but it’s a big deal. It is not a small accomplishment. And I’m just wondering how you would describe that or compare that to give people an appreciation for what that represents.
Adam Gazzaley: Yeah, it’s around as big a thing can happen as a scientist. And probably, if it happens at all, will happen once in a lifetime. Having a paper in Nature or Science, those are the pinnacle journals in the world. Those two, the twin towers, and having a paper in them is incredibly rare and exceptional. And then having a cover story is just a once in a lifetime. And my friend, Mickey Hart, who’s a musician, he’s the drummer from The Grateful Dead, he always jokes that “Oh, that’s a cover of Rolling Stone.” So everyone sees it through their own eyes. But to me, I think it’s like a Grammy and it’s a mixed feeling about it because you get it and it changes your life, and it did. But you’re like, “Oh, that means that was the pinnacle of my life and everything after that is just not as good, it’s not going to happen again.” And I have tried again and we’ve had some really great papers over the years, but in all likelihood, that’s the only time that’s going to happen in my life.
Tim Ferriss: Well, never say never.
Adam Gazzaley: That’s true. I’m going to try. I’ll keep trying now.
Tim Ferriss: So a few other there’s things I’d love to note. So the next is that you, I think, are very ambitious and calculated at the same time. So on one hand you might say that you not just enjoy, but look for risks that you can take, say related to the video game connection, because you don’t want to be, you personally and then I think by extension to your lab this would also apply, but you don’t want to be the scientist who is simply building on whatever came before in an iterative, incremental approach. Is it fair to say that you are looking for groundbreaking discoveries or the groundbreaking development of tools? Is that a fair statement?
Adam Gazzaley: I’ve always been motivated since I was a little kid and when I thought about science and thinking about the giants in history, whose names you still remember millennia later, those were my heroes. Not the baseball players or musicians. It was always those scientists. And looking at their accomplishments was what got me so excited about going into science in the first place. And when you approach science in that way, you realize that wanting to do it is only a piece of the puzzle of getting there and even having the ability and skills to do it is still only a piece, it’s a convergence of those things and time, frequently other events that are outside of your control that all lead to a moment where you get to make a contribution at that level.
And that was always my dream, but it doesn’t mean it’s going to happen, but to answer your question directly, in order to get there, I tended to think about the research that I wanted to do from that perspective. And not just because I wanted a big claim to fame because that’s not a great goal, but my real goal is to make a meaningful difference in humanity, in the world, and help people. And I felt that in order to do that, you really have to step out of the box, so to speak, and not be iterative and do the thing that takes a little bit more fearlessness and a little higher risk, and it’s okay to fail. But if you don’t try, then there’s no chance that you’re going to make a difference at that level. And so that’s how I’ve always approached it along my career. And now that I’ve had some successes in it, you get even braver, I would say.
Tim Ferriss: And I want to give a few more examples of the types of tools and work that you do within your lab. I’ll first just read a quote from our first conversation, it was in response to me asking what makes your lab unique, and please feel free to fact check this, but I believe it’s accurate. The question you asked yourself is how can we use our expertise or methodology, our perspectives, to not just understand the brain, but to try to develop novel approaches to enhancing it, and then validating that our approaches are actually effective? That, I believe, was in the first episode and in the process of following that question you, for instance, studied how electrical currents can enhance brain function in non-invasive approaches with things like tDCS.
And this is, I suppose, as good a place as any to segue to a new addition to your bio, which refers to this FDA clearance of a video game. What does that refer to?
Adam Gazzaley: My goals have always been to not just have a super long CV with lots of recognitions and awards, which is often what scientists, even my great friends who I respect dearly, are building. I wanted to do research that then leapt off the page and became tools that would enter people’s lives and make a meaningful difference to them. And I quickly realized that I could not do that within the chambers of academia alone. I had to leave and not necessarily leave, but I had to cross over. I had to find a way to move technologies and invention and discovery from the lab into the real world. In order to do that, it involved working with industry in some way. You don’t really produce scalable products in labs and academic labs. It’s just not structured for that.
And so the NeuroRacer technology, the video game, and really the methodology behind it, which was a patent that I filed at UCF that is now issued. It took six years to issue that. With that technology, I co-founded a company called Akili Interactive with friends from the video game world and Matt Omernick as well as Eddie Martucci, who was working with PureTech Ventures in Boston. And we started this company Akili Interactive to move that technology, and the Nature paper wasn’t even out at the time that we formed the company, beyond a prototype and an academic exercise that leads to a paper. Even a paper as good as a Nature paper, that wasn’t the goal. The goal was to turn it into a product that would be a medical device that can actually serve as a new form of medicine beyond the molecular medicine as what I now think of as an experiential medicine or a digital medicine that could lead to improvements in attention in different clinical populations.
And so over the last seven years plus, we’ve now at Akili, we’ve built a better version of NeuroRacer. Better meaning that it has higher levels of art and music and story and interactivity and feedback loops and usability, but preserves the same underlying architecture, the same mechanism that is defined in the patent that was in NeuroRacer is in this game called EndeavorRx. And over these many years, Akili has sponsored research at academic universities to validate this video game, this child of NeuroRacer, as a clinical tool, as a treatment in numerous populations. So studies in autism and depression, ADHD, multiple sclerosis have been published now, all converging on the same conclusion that this game can improve attention abilities in these different populations. So even if there’s a different reason why an individual has an attention deficit, because they have a sensory processing disorder as a subset of autism, or they have depression, we see the same benefits, which is really exciting because you get that really broad effect.
And so to go back to where you introduce this, a study was done out of Duke. I was not even an investigator on that study, that’s the dream, right? That you create the technology and then other colleagues and other independent investigators validate it. So this was a study out of Duke by a really great clinician scientist, Scott Kollins, and it was a really unique study methodologically because it was a multi-site, double-blind, placebo-controlled trial with a video game in children with ADHD. So 350 kids. Years, millions of dollars of big — actually not the type of studies I like to do at all, but a big, important study, it’s called the phase three trial. So it’s a pivotal trial. It’s the type of study you do that you pre submit to the FDA, all your design elements, your outcome measures. It’s like a baseball player pointing it to the distance thing, this next shot is going to be this home run and how that’s so much more meaningful because you calling it in advance. That’s what you do in these studies. You have to pick your outcome measure and what you expect to see before you even do the study because that’s the most statistically rigorous way to show that this is a true effect.
And that’s what was done in this study, the hypothesis was that the sustained attention of these children, which is very impaired beforehand, they have ADHD so sustained attention is vigilance in a really boring environment, it’s designed to be boring, this test, that that would improve in response to this video game compared to another group of children with ADHD that’s playing a different video game. And so that study took years and that hypothesis was confirmed that those children did improve.
The other group, the other game didn’t change at all. And so it was specific to this game EndeavorRx. And with that finding we, as Akili presented to the FDA, the results requesting approval for clearance of a medical device, it’s actually a class two medical device to treat inattention in children with ADHD. And that took many years. Just a point of detail, if folks are interested in this, that’s known as a De Novo pathway. There’s two pathways through the FDA for either a drug or device. One is De Novo, meaning it’s completely new. There’s no predicate. It’s essentially establishing a new category of treatment. And the other is the predicate, the 510(k) pathway where it rests on a previous history. And so it’s much faster to get approved through that pathway, then the De Novo, the new pathway. And so, because there had been no video game and no treatment of this type ever cleared by the FDA, it was a De Novo pathway, which made it a lot longer and more rigorous of a review process.
But we found out during COVID, just in the summer of 2020, that the game was cleared. So this was one of those small blessings as my friend Michael Pon said, “A silver lining in the pandemic blanket.” And so what we found was, as we went through this process, the FDA was willing to clear this as a treatment for inattention in eight- to 12-year-olds, that’s what the study was done on, with ADHD. Which was just an amazing result after a decade of journey from NeuroRacer to this, because now what we wound up with was the first ever FDA clear digital treatment for children and the first digital treatment for ADHD and the first video game for any clinical condition. So it was a long journey. And I want to give all the hundreds of people at Akili and Neuroscape credit, as well as the independent investigators, like Scott Kollins, for all the work and pushing it through but now we have an entirely De Novo treatment of this type out there for kids.
Tim Ferriss: This is exciting to me on multiple levels. One is that, as you mentioned, it’s De Novo, this is a, in several senses, establishing and validating a new category. I mean, that’s a new category of treatment or intervention. And one question that pops to mind is what the underlying mechanism is, or if you can explain why the game EndeavorRx seems to be effective in multiple populations? And you named a few, depression, ADHD, autism, or certain types of autism —
Adam Gazzaley: Multiple sclerosis, we’ve now found.
Tim Ferriss: Multiple sclerosis. Even though these conditions manifest and present in very different ways in a bunch of respects, what is the commonality, or why is the intervention effective across these different conditions?
Adam Gazzaley: Yeah, it’s a great question. And a complicated, longer answer would probably be required to really break it down, but to just give at least a basic understanding of how that’s possible, it really is through the window of cognitive neuroscience that that makes sense. If you look at the pathology of those conditions, it’s more confusing and elusive of why they would be connected to have a common treatment lead to benefits across them. But from a cognitive neuroscience perspective, which is my background over the last couple of decades, is that there are common underlying neural networks in the brain that subserve different abilities, like attention, memory, decision-making, emotional regulation, on and on. And these networks could be damaged, influenced in all sorts of ways by many conditions due to different reasons. When it comes to our attention systems, the networks are so distributed that I would be bold to say that any real insult to the brain that leads to any cognitive deficit is going to have a component of attention deficit associated with it. So if you look across all the neurological and psychiatric conditions that you could think of and put it into PubMed or Google Scholar with the word “attention” or “distraction,” you will find research showing that they have impairments in that. And that’s just because the act of focusing our limited mental resources on something that is a goal of ours, which is the core of the type of attention we’re talking about, sustaining selective focus on something that you choose to, top-down attention. That process involves so many distributed brain areas that all these different sources of pathology lead to decrements in that ability.
So if you have an intervention like NeuroRacer and EndeavorRX, which challenges cognitive control at a very high level due to closed-loop systems in a personalized way, like the ultimate trainer constantly pushing and optimizing those abilities over weeks and even months sometimes, then what you wind up with is a transfer of benefits to cognitive control challenges outside of the game that’s independent of what the cause of those deficits were. I think that it gives you a bit of an idea of how you can have an outcome that sort of crosses all these boundaries because the same networks are vulnerable in all these populations. So anything that can optimize them could lead to a benefit across them.
Tim Ferriss: Could you, for people who don’t have any real perspective or context on UCSF, just describe UCSF? What is UCSF from the perspective of research or looking at it as an institution of science? What is the best way for people to think about UCSF in the ecosystem of research within the United States?
Adam Gazzaley: Yeah, it is a massive and humbling honor for me to be at UCSF myself. It was always a dream to come out here to California and work at this institution. A lot of people don’t know UCSF, University of California San Francisco, like they might familiar names like Stanford, Harvard, MIT, largely because UCSF is only a medical and health center. We do not have an undergraduate campus. There’s no engineering department, everything’s bio: bio-engineering biochemistry. But it is one of the world’s premier medical centers, pretty much across every domain, especially in neuroscience, neurology, neurosurgery, psychiatry, and those areas. And the brain area is UCSF’s forte, from many perspectives. It’s always ranked as one of the top in the country and even at world measures when it’s put to the test or different evaluations.
From my perspective of being a faculty member here for now 15 years, it’s amazing. Every other faculty member I would meet, without knowing anything about them, I’m excited because there’s something about them, of why they’re here at UCSF, that I just want to find out. And then of course from just a clinical perspective, I would send anyone in my family without hesitation. Yeah, it’s just a wonderful, wonderful place to be a scientist.
Tim Ferriss: I want to come back to the risk-taking, the concept of risk-taking for a second. And then we’re going to talk about new chapters. We’re going to talk about new areas. When I hear you talk about risk-taking and translating science into the world for impact, it strikes me that on one level, you could look at some of the projects and things that you’ve done as risky in the sense that there’s a possibility that they do not work and they’re, in many senses, not incremental. You’re not just adding an extra five percent on top of something that’s already been demonstrated.
At the same time, when I look at how well you’ve been able to recruit and how well you’ve been able to retain and how effectively you’ve been able to build and grow, this is a leading question, obviously, but would you agree that that ambition and the willingness to take things that one might consider risky on as projects is a critical ingredient in all of those things? I feel like to foster an environment where you can do all of those things, where people will put in lots of hours and effort over a long sustained period of time, like you mentioned, the years required for some of these breakthroughs, that that risk-taking seems to be a critical ingredient, almost a prerequisite for that type of enthusiasm. That’s at least my perception, but what are your thoughts?
Adam Gazzaley: I agree with you. I think that’s part of it. When you create an entity, I think at the time that we last talked, it was my lab, it was Gazzaley Lab. That’s a pretty classic way of how labs are named after the PI. Since then, my lab has just exploded. Now it’s not a lab anymore, it’s a center where there are multiple faculty. We have now seven faculty members.
I think the reason that that has happened is because of the type of risk-taking that I am willing to do, but also how we build, we, my whole team, builds a system of security in that risk-taking, because it is a long time to go without a publication when you start one of these types of studies. It can be five years before you’re even writing up a paper.
Therefore, in order to jump off of that bridge with your bungee on, you have to have security in the bridge and in the bungee and in the instructors and the person that ties it on. It’s a whole community effort to create the platform that allows risk to be taken in an appropriate way. Because if we were just reckless, who would join that and where would be the means to assemble an all-star team of staff and postdocs and students and faculty? They wouldn’t gather. So I agree with you. I think that’s all tied together of what it means to take a risk, to do something bold, but to do it in a way that’s thoughtful and not reckless.
Tim Ferriss: And you used a term, just for people who may not recognize it, you said “PI.” That is not Magnum. P.I., private investigator.
Adam Gazzaley: Sorry.
Tim Ferriss: It’s principal investigator, if I’m getting it correct.
Adam Gazzaley: Correct.
Tim Ferriss: Yeah, which refers to the lead researcher for a grant project. How many folks do you have within the Neuroscape endeavor on that team?
Adam Gazzaley: Neuroscape’s a center, we just call it Neuroscape. We have over 40 people on payroll now. And we also work with a lot of contractors and volunteers, and that number is well over 60. So it’s a big group, and it’s been quite a change for me as a PI, as a principal investigator, to become a director and to really help other scientists upcoming in their careers to spread their wings and to really take those calculated risks as well under this community of Neuroscape that we created.
Tim Ferriss: It’s so wild, Adam, I just have to say, to think back to when we first started spending time together, looking at the evolution of the bio, re-reading it for the podcast, just the change since 2015. Seeing how much you have done since I took also my first step into the world of scientific research from the standpoint of funding with that very first check.
Adam Gazzaley: Yeah, whenever it was. Which I think was 2012.
Tim Ferriss: Yeah, 2012. Something along those lines for Gazzaley Lab. And it just makes me so happy to see how incredibly well you’ve been able to execute and not just execute as an independent sole scientist, but also assemble and retain top talent. It’s very impressive to me. I just wanted to say that.
Adam Gazzaley: Thanks. It’s also fun. It’s always a real pleasure to talk with you, Tim, because we have so much history, going back to over a decade when we met. I can’t help, like you’re doing, is thinking back in those early days when you even joined us for a bit on some brain stimulation work to help us out in the lab.
Tim Ferriss: I did.
Adam Gazzaley: Just how much has changed since then. It’s fun to think back, not just what the list of papers are, but the actual journey and what was involved in assembling the people and the uncertainty, even when we were talking over the years where it was not FDA-cleared and it was uncertain if it would be because of all the challenges of going through a De Novo pathway. So it is really gratifying to talk to you now, after all these years, and see where we’ve come.
Tim Ferriss: Yeah. I remember trialing very, very early versions of NeuroRacer with the cap on.
Adam Gazzaley: Yeah, EEG.
Tim Ferriss: Right, exactly. The EEG cap on, and also having you help, I think it was my middle finger, to jump, kind of dance around with the TMS applied to, was it M3?
Adam Gazzaley: Yeah, motor cortex. Yep.
Tim Ferriss: Exactly. It’s been a hell of a journey, man. And it’s not over.
Adam Gazzaley: No, not at all.
Tim Ferriss: I think it’s fair to say you’re in a position where you get to pick your targets. I mean, you’ve done exceptionally well. You’ve established incredible, defensible credibility. You’ve had a game changer, NeuroRacer, on the cover of Nature. You have this well-developed center, Neuroscape, which is not just up and running, but really humming.
Adam Gazzaley: Yeah.
Tim Ferriss: It is a formidable organization. You can really choose what you want to do and what you want to focus on. So I suppose this is as good a place as any. Could you please tell us about what the new undertakings are? And I suppose the announcement. We could start with the announcement and then go into backstory just to hear how you got to this point, or we can start with the backstory and then get to the announcement.
Adam Gazzaley: I agree. Let’s not bury the lead. We’ll tell what’s going on and then we’ll break it down so that everyone could enter this conversation with that full knowledge. So over the next couple of weeks, we’re in the process of announcing, we’re going through this right now, a new division within Neuroscape that will focus on psychedelic research. So Neuroscape Psychedelic Research Division is being launched, and we’re very, very excited about it. We’re also really excited that this division will have at its home Robin Carhart-Harris, who will be joining us as a faculty at Neuroscape and will be the director of the center. And that’s incredibly exciting for me. Robin is a leader in the field of psychedelics, has become a very good and trusted friend, and I’m honored and humbled in many ways that he’s willing to travel across the world over from the UK to join us, to be the founding director of this division within Neuroscape.
He’ll also be coming with an incredible position, the Ralph Metzner Distinguished Professor of Neurology and Psychiatry. Incredibly excited for him to start his new journey within UCSF and within Neuroscape and to advance psychedelic research to the next level. So that’s the lead. And we can talk about how all that happened.
Tim Ferriss: Yeah. Let’s talk about it. I also want to just note, because I find it so incredibly inspiring, that things happened very quickly. Not just quickly for within the scientific sphere, but quickly, period. If I remember, you look back at email threads, just looking at the sort of time period that transpired after you first connected with Robin, and as everything unfolded, it was very fast. I think that’s extremely inspiring and demonstrates what’s possible within universities and teams that are able to embrace this as a direction. I just think it’s incredibly impressive.
Adam Gazzaley: I’m really pleased with how rapidly we’ve been able to do this, especially during COVID. Nothing really seems to happen fast these days. It’s a reflection of the people involved, the university and the fit of all those things together: the people, the university and the research mission, which is what I’d love to spend time talking about. Those things allowed it to move so rapidly that it just felt right and made sense from pretty much every perspective. Not that there wasn’t a lot of logistics and politics and negotiations, but the core of why this was the right thing to launch this division within Neuroscape, to have Robin lead it, it just makes sense. With that force, all the other pieces fall into place.
Tim Ferriss: Yeah. Well, with a big enough “why” a lot of the other things fall in line. How did this come to be? Please share whatever you think might be helpful to paint a picture of how and why this came together.
Adam Gazzaley: Yeah, that’s great. I’ve never really told this story yet, and I was sort of saving it to tell with you, because you were one of the inspirations in it, not just a friend of mine. If I go back to 2019, which is not all that long ago, and even into the sort of mid and late 2018, conversations that I had with friends, including you, about psychedelics as a medical tool, really ignited my imagination. And this was sort of converging with my own goals of thinking about what I was going to do next as a scientist, as an innovator to not be iterative.
I’ve had the success with video games as a therapeutic tool. This was before the FDA clearance and there’s so much more work to do in that domain and we will do it. It’s a lifetime of effort to continue to advance that. But I was thinking about the next decade, moving from 2019 into 2020 and beyond. And I was looking for something that was not brand new. I don’t want to plant a new tree. I’ll have more branches, but I’m not going to start over from the beginning. It had to be within the scope of where I felt my expertise lied, what I enjoy doing, the methodology and the skills of my team at Neuroscape. So it had to fit in that picture. I started exploring what that would be. And when I heard my friends talking about psychedelics, I live in San Francisco and certainly a lot of people here have for decades —
Tim Ferriss: Easy to find that conversation.
Adam Gazzaley: Easy to find that conversation, exactly. I never really thought about it from a scientific perspective, as a neuroscientist in that way, which sort of says something, right? I did an MD and a PhD. I did a full neurology residency at UCSF. How come never during all of that training was psychedelics ever presented in an academic manner as being a potential tool? Not once, never, which is fascinating.
Tim Ferriss: It is.
Adam Gazzaley: And we know a lot of those political and social reasons why that’s true, but it’s still mind-blowing when you think about that, given all of the neuro-education that I’ve had over the last 30 years. But once I started thinking about it, I decided to dive in a little deeper. The first thing was reading Michael Pollan’s book, How to Change Your Mind. I know you’re also friends with Michael and I did not know him at the time.
We’re close by geographically. He’s at UC Berkeley and a professor there. I’m at UCSF, right across the Bay, half an hour away, but we never met each other. And I read that book and something did change in my mind. It’s really clear what it was. It wasn’t just that I saw the clinical potential of these compounds. That was obvious and I knew that already. What happened when I read that book was that I realized that these are not really molecular treatments. They’re not drugs in that classic sense of “introduce a molecule, lead to an effect,” right? Just pop this in your mouth and your cold is gone, sort of like, in the infectious disease world, how we think about drugs.
I realized that these were experiential treatments and experiential medicines in much a similar way to what I was doing with video games, that it is the molecule that initiates a series of events in your brain that leads to an experience. And that experience leads to an outcome. And that outcome could be good, or it could be bad, but it doesn’t just depend on the drug. It depends on the intersection of that and you, and the context around you and the experience itself. That was an epiphany for me. Maybe it was obvious to others, but I just never really thought about it from the same perspective that I was engaging in our work at Neuroscape, which is creating these experiences as medicine. Once I realized that, I was like, “Oh, this is it.” This is the area that I can contribute to in a unique way, because of the work that I’ve done at Neuroscape. And also, I believe, elevate this field, because it is the area of psychedelic research and psychedelic science that I think is most efficient and missing in order for it to translate most effectively.
And so with that, I began a journey, throughout 2019 and 20, to meet the people that were shaping this field, to read the literature and really understand the potential here. So everyone from Michael Pollan himself to Robin Carhart-Harris. I went to gave a talk at Imperial College in Oxford, in the UK. Rick Doblin, you, and I talked a lot and you made other introductions, and I started expanding my mind about the potential for psychedelic compounds to lead to really profound and transformative outcomes through experience. That was the part that really captured my imagination.
Then I started really reading Robin’s papers carefully, and he has a lot of them. He’s the most cited researcher in the field. He’s a young guy and I just really respected what I saw from him as a scientist, his own risk-taking, but his rigor and the depth that he approaches a problem, the review articles he wrote.
And then I started reading about his articles on context, which is essentially what I’ve been talking about, how the elements, what in the field is known as “set and setting,” how you enter into a treatment. What is your makeup already? What are your intentions and what occurs during it? What do you hear? Are you listening to music? Are there other elements of safety around you that take you through that experience to a certain outcome? And he’s written about this both at the sort of review article level where he’s surveying the field, and then from work that he’s done himself with music during treatments.
So I was inspired by his work, but I also realized that what I was seeing was that everyone in the field that I talked to, whether they were therapists or shamans from South America or researchers at Hopkins, everyone agrees that this element of context, that the experience itself is critical for the outcome, is universally agreed upon. I’ve never heard, really, any deviation from that. But the ingredients that go into the recipe of that experience that lead to the most favorable and enduring outcomes is unknown.
Now, there are definitely therapists that have experimented for many years with context and are experts in it. But if you’re looking for prospectively designed, randomized trials that have started dissecting these elements and learning who they work best for and what conditions, there’s almost nothing in the literature that shows that. And so once I really realized that, I said, “This is an incredible opportunity to make an impact in a field that already has so much potential and to really fill in that gap that I saw.” And then it was meeting Robin, finding each other, sharing this passion and realizing that we could do more together and that Neuroscape is a perfect environment in order to do this type of work because of the effort we already had in experience as medicine.
Tim Ferriss: And as you said, it seems like there’s quite a bit of basic science that’s been done. We have the clinical trials, advanced clinical trials, later-stage clinical trials, but there is this, in a sense, gap in the middle. There are people who will have contexts that they decide or assume, or perhaps on some level, even test to be effective that they take through trials, but they’re not doing, and this is going to be maybe a primitive way of looking at it, the sort of multivariate testing, because they don’t have the expertise or the equipment to do so. They don’t have the team to do so, but you have a multimodal biosensing capabilities, multisensory integration work within Neuroscape. So I’d be curious to hear you speak to what capabilities you’re looking forward to exploiting in the exploration and testing of these things.
Adam Gazzaley: Yeah, let’s dive into it. I just want to pause because we may have went over it a little fast. This sits in the middle between what? I didn’t really clarify that. The reason I say it sits in the middle is because, let’s say on the left side at the beginning, there’s all the really great basic science. This is the work that’s done in a dish of a culture of neurons or in animal models, and understanding what these compounds, LSD, the elements of psilocybin, what they’re doing at the level of the cell. Are they anti-inflammatory, are they plasticity-inducing? Really just the basic — what receptors they bind to? An incredible amount of great work in that domain.
And then on the other side, let’s say the right, there is all the advanced phase two, now approaching phase three, clinical trials. So these large multi-site trials with populations in need, like post-traumatic stress disorder and depression, alcoholism, end of life, treatment addiction, amazing clinical work showing benefit. So the middle is all of the stuff that you need to go from the basic science insights into the clinical trials. That is the middle that we’re talking about is missing. How do you optimize the delivery? How do you make it personalized to the individual? How do you make it precisely targeted to those neural mechanisms that most need to be improved? That’s the area. That’s the middle that I see pretty much completely vacant. And that’s the opportunity that excites us at Neuroscape, that we want to explore. So now that I think I defined that area, that opportunity a little better, let’s dive into how do you do that.
This is another intersection that I find fascinating, and have for a long time, is the role of technology in neuroscience and not just in the research, but in its translation. A perfect example is a video game as a technology that we have now used as a research tool and now have cleared as a therapeutic. How can technology play a role in understanding the middle, the role of set and setting in inducing a positive outcome? There are really two ways that I’m excited about proceeding with that. And our team at Neuroscape is already proficient in that. So we’re quite prepared for Robin to land and then sort of —
Tim Ferriss: Hit the ground running.
Adam Gazzaley: Hit the ground running. We’re writing grants. We’re buying equipment. We’re already running, even though he hasn’t arrived here yet. Let’s think about it this way. Here you are. You could imagine yourself going through a treatment like this at a university. You’re taking a compound. Maybe you’re familiar with it, maybe you’re not. Let’s say, psilocybin. It’s a reasonably high dose. You’re going to have a pretty strong experience. Our goal is that you end up on the other side of the experience in at least the same place, hopefully, a better place. Right now, if you were in a study with that design at a university, anywhere in the world, you would likely be laying down with a therapist. You would have already had several sessions. You would have been well prepped. There would be that element of set of going into this.
You would have been screened for conditions that might interact unfavorably with this treatment, like schizophrenia and other conditions that are avoided, at least for now. You would then ingest this and have usually a blindfold on, an eye mask so it was more internal. You weren’t seeing things. And you’d be listening to music. That music would vary across site. It may not even be music that you actually like, but that’s the design right now. You would have the support during the session. And after the session, you would have several other therapist-led meetings to help process and integrate what you went through and then follow up. That’s the basic design. And it’s a good one. It’s one that we’ve been really using for decades, even in the ’60s, similar designs to this. It’s good methodology and it’s getting better and better.
What I see missing there in understanding the middle part is, the first thing is we don’t really know what’s going on with the participant during the treatment itself. You’re sort of a black box. Now, an extremely good therapist that has done this for 40 years is picking up subtle verbalizations or body movements or changes in your facial expression. They’re able to protect you if you need it or help, just sit with you as you go through some challenges and that’s as good as it gets. But that’s not really scalable at any level, because you can’t have as many experts as there are people in need of a treatment like this. So that’s the first opportunity. And I’m going to talk about that in a moment.
And the other opportunity is, well, is a blindfold and a mask the best option? Is music really ideal? And what type of music? What about all the other senses that we have? How we smell and feel and other aspects of hearing that are not being used during these treatments? Unknown. Used in the real world of therapy, but not really studied. We don’t know who they’re best in. So that’s the second domain.
Let’s split those off. The first domain is recording. We have a system at UCSF. We call multimodal biosensing. My hypothesis is that with enough sensor technologies, not just looking at brain activity, but looking across the whole spectrum of physiology and behavior, so high density EEG, facial expression, electrodermal activity, heart rate and its variability, looking at facial expressions, body movements, doing experience sampling either through vocalizations or using joysticks so that there is some degree of communication, my hypothesis is that not one single of those signals are going to tell us about the state of that individual during a treatment. But if we can collect them rapidly in real time and integrate them, use machine learning approaches so that we can look for the patterns of what’s the most meaningful data, we will be able to plot the experience landscape of an individual traveling through a treatment like this.
We won’t know the content. We won’t necessarily know that they’re picturing the details of a traumatic event in their lives. But I believe that we will be able to tell their level of arousal, the valence of it, is it positive or negative? So putting that together. Their stress, the state of stress, their attention, whether their attention is internally directed or externally directed, as well as, hopefully, even a sense of their awareness of what’s going on. So real time state recording as implemented through multimodal biosensing. That’s a very high-tech endeavor, but it is possible right now. It takes a real multidisciplinary team. You’re talking neuroscientists as well as people on the clinical side, biosensor technology experts, signal processing, machine learning. It is a real challenge and it has not been accomplished yet anywhere in the world at any level that allows us to really track state.
So that’s the first challenge that we want to really tackle, is using technology to understand the state of the person while they go through a treatment. The other side of it is starting to manipulate all of these levers of contexts of the setting and the set. So how do we position them through different information that presented different environments before the treatment? And then during the treatment, not just think about music with eyes closed. Sure, we will do that. That is the standard approach right now, but what is it like to look around you? To see either light or abstract views or views of nature? To smell a forest when you see it and when you hear it? What we call multisensory integration. To feel low-frequency vibrations through your body as you enter into these different environments? All of that is unexplored.
By putting these things together, we start understanding the journey, the journey within the treatment itself. How these little, not little to the individual, but these discrete moments in time, these micro experiences along the way, how they’re influenced by the context of the environment that we’re able to control around the participant. And then how all of these elements add up to an outcome, to a sense of well-being or joy or mystical perspective that occurs after. So how do we connect the events that occur during the treatment with the outcomes? All of that is unexplored. And that’s basically what we’re going to be focusing on.
Tim Ferriss: There is so much room for experimentation. So many variables. There’s a lifetime there.
Adam Gazzaley: Oh, I always say to Robin, I was like, “We will die before all that, that you just heard, is figured out.” There’s so much.
Tim Ferriss: It’s incredibly exciting to me for many reasons. Just to give a snapshot of personal experience here, that raises questions, I think, related to those that you’ll be exploring in a very methodical, tech-enabled way so that you can actually measure, capture and quantify these discrete events, discrete changes. I recall the first time I did a five-session series of infusions, this is intravenous infusions of ketamine. In this case, I wasn’t using it because I was suffering from acute depression, nor chronic pain. Those are two indications, but I wanted to be able to speak to the effects and possible side effects, after effects of ketamine treatment, if I were asked, which I knew I would be asked. What really stuck out to me, among other things in this ketamine treatment, that it was the first time I had been seated in a chair and that video had been put on for me.
I was asked to select a DVD. It was very retro in that sense, but, and I was able to choose a DVD that I then used as a constant throughout my sessions. I didn’t change the video, because I didn’t want that to be an uncontrolled variable. I’m not pretending that these are really tightly controlled, but I was trying to minimize the number of variables. So I kept this constant as this video. I’d never, in a deep psychedelic experience, which you can certainly have with ketamine at sufficient enough doses, even though it is a bit bizarre as a dissociative anesthetic, I’d never had the experience of attempting, even attempting to watch video in these states.
So to observe how the imagery, and this isn’t, I suppose, on some level, surprising, because internally generated imagery can certainly have a tremendous effect, but to observe how the imagery affected the experience, how the music on the video affected the experience, how closing my eyes or opening my eyes while being exposed to this external stimulus affected my experience was very new. It was very novel to me. That’s not what usually happens if you are in a supervised setting, certainly within a university context. It’s more or less what you described. It’s like, “Okay, eyefolds on. Lay down.” We have pretty good evidence to suggest that this at least doesn’t interfere with reasonably good outcomes, but there’s so much fine-tuning and assumption testing that can be done and that you will be doing. It’s incredibly exciting to me.
Adam Gazzaley: That’s great to hear. When I first started putting the meat on the bones and saying, “Okay, this is something exciting. Robin’s interested. My leadership at UCSF is behind me creating this,” I felt nervous, because this is a new field to me. It has a lot of history. There’s a lot of therapists that have been doing this for decades. Obviously, the indigenous cultures around the world have used these as not just mental health tools, but as religious and spiritual. I wanted to dive into that part and determine if anything that I have just said to you is offensive to them. I just was curious how it would be received, because it is very, very different than how these experiences are often delivered throughout history.
I was really surprised to find that, especially on the multisensory stimulation side, therapists that I talked with were really receptive to it, that they thought that this is actually what they mean when they say shamanism. It is this act of environment tuning and creating to help guide that journey. They feel that they may be pretty good at it, because they’ve been doing it for a long time. But they were certainly open to having data that they could reach for that would give them more fine tuning. And also recognizing how hard it is to train people that are new to this and that if there was a library of stimuli and an evidence of who it works and how it works, and also their ability to know what’s really happening inside an individual’s mind, they were very, very activated by that. Now, I’m sure that won’t be true for everyone, but that was really reassuring.
The last point I want to make on this was my big goal here is not to say, “We don’t need therapists anymore. We don’t need humans in the loop. We have enough technological advancements in terms of sensor technology and machine learning and artificial intelligence that we’re good. We just need you to take this, step into the box and come out fixed.” I really, actually do not believe that that is the future we will or should have. I think that what we’re doing here is building a set of tools, really sophisticated, informed, data-driven tools that will allow a therapist or any practitioner in the space to be more effective at helping their patient. That is what I hope and believe will come from this long journey. And that technology will be what it always should be, is just another human tool. That’s where I hope and do believe that we will end when we go through this research approach.
Tim Ferriss: Looking at Akili and EndeavorRx for a moment, because I’m tying these things together in my own mind. I’d love for you to stress test what I’m about to say. In treating not just children with ADHD, but patient populations or populations with autism, with depression, these different conditions and talking about how it is possible that a single intervention can be efficacious across multiple conditions. This conversation or related questions translates quite well to the study of psychedelics. Certainly, Robin Carhart-Harris talks a lot about the default mode network and how and why it appears that some of these compounds are therapeutically effective or at least appear to be, or the data suggests they are effective across a pretty wide range of conditions that most or many people would assume are not related at face value. You have different types of addiction, including alcohol use disorder, opiate use disorder, that’s opiate use disorder forthcoming at Hopkins, and then you have PTSD.
You have treatment-resistant depression, as well as major depressive disorder. There are people looking at OCD. And one of the assumptions of which, or one of the assumptions underlying the cross efficacy, is that perhaps there’s this commonality, this neurological correlate with the default mode network, that there’s a rigidity associated with these various behaviors that is attenuated with psychedelics. I’m just, in my own mind, observing a similarity between the software development and then the testing within psychedelics you’ll be doing. The question that I have is, do you envision looking at how much is, I guess, automatically achieved with software? There’s an adaptive component where you are able to determine over time, for a single subject, a sequence of experiences that is adaptive in some way. Does that make sense?
Adam Gazzaley: Yeah. It makes total sense.
Tim Ferriss: You mentioned this earlier. And just in case some listeners didn’t catch it, the EndeavorRx adapts to the user. It’s like a personal trainer who increases the weights and certain movements over time so you have progressive resistance and therefore, greater adaptation. Do you think that that is an area you’ll be exploring or that you would like to explore, how you can adapt a series of psychedelic experiences for an individual to be customized?
Adam Gazzaley: Undoubtedly. It was really, really a great statement and question, that I want to just take a moment and unpack from my perspective, because I think, as we’ve had this conversation, people could be lost, “Wait, are you building video games? Are you working on psychedelics? Where are the threads here?” It is the same thing that we’re talking about all along. This is the power of experience to change the brain, what in neuroscience would be known as experience-dependent plasticity. Whether that experience occurs with or without a molecule, it has the power to transform you in an incredibly profound way. It could be positive or it could be negative. That is what PTSD is. You could just witness something so horrendous that your brain functions differently from there on out. That is the negative side of this story.
That is what I’ve been working on, how to build experiences. We do a lot of work with virtual reality now, multisensory experiences. I believe we’ll have even more profound outcomes and more transformative effects. We don’t put any compounds on board. That’s what Neuroscape basically does now. Now, expand the conversation. We’re talking about these psychedelic compounds. There’s a broad array of them so we won’t break them all down. They’re all different in some way in the effects they have. But they really have these two features that are most fascinating to me. One is that they shuffle the deck in many ways. They break down the rigid frameworks that you go into the experience with. And that is a combination of changes in default network. There are many networks in the brain, big, large-scale networks. Their interaction leads to you and leads to your consciousness. So those are shifted, leading to the opportunity to reform them. And then they also —
Tim Ferriss: Adam, let me just pause here for a second. When you say they lead to you, that means your conception of self? Like when I say, “I am Tim,” is that what you mean?
Adam Gazzaley: Yeah. From every level, your ego, your reflection of your identity, but also your position in space and in time and your relation to other elements of the universe and the world around you. All of that is more fluid. That is because these networks that may dictate your own reflection of who you are or how time is passing or how you perceive light or sound or touch are distorted from the norm, thus allowing a complete rediscovery of you and the world around you. That’s one very profound piece of it. The other is that they induce neuroplasticity. Robin talks about this all the time when he presents his work. That is also incredibly fascinating, because it’s not just that these compounds enrich or change an experience, which they clearly do. They also are plasticity inducing, meaning that the changes that occur have a greater potential to endure.
Now, this would be really a bad thing if you have a negative experience, which is, I think, part of what has occurred over the last half century, is realizing that in an uncontrolled environment, that you may be threatened while on a compound like these. The effects can be way worse than if you were not on them. This is the yin and yang, the plus and minus that everything has, is that we now realize that the experience, since that is what evokes the outcome, needs to be positive. Or at least, not that suffering can’t occur, but at least needs to be nurturing in a way that leads to a positive outcome. I just wanted to make that connection, is that it’s really about experience and large-scale neural networks that cross multiple domains and plasticity. That is the common feature that unites all the work that we do at Neuroscape, whether it’s non-invasive brain stimulation, new approaches to neurofeedback, video closed loop, video game technology or now psychedelics.
Just to put that together, because you made the leap between EndeavorRx and this work, and now to just answer your question more specifically about closed-loop systems. So let’s just put pause and just make sure that everyone’s on the same page with that. Probably what makes EndeavorRx so unique, as well as the dozen other video game technologies that we have at Neuroscape from MediTrain to Engage, Labyrinth, we just had a paper on, Body Brain Trainer, they’re all closed loop. What that means is that real-time data about your state, and it may be very simple data like your performance data, how fast or accurate you are, feeds into a processor, a computer, that records that data, makes a decision about it and then updates your environment. The challenges that you’re experiencing, the stimuli, the rewards that you’re being exposed to, and it goes on and on constantly adapting.
That’s why I made the analogy to a personal trainer. Imagine going to a gym and having a trainer that has access to every aspect about you in the moment. And also this ability to change things so subtly, to just push you to the next level. That is what this closed-loop system does. Now, we’ve been doing that for a decade, with all sorts of experiences delivered in virtual reality and on tablets. Some of them are eyes closed, meditative experiences. Others are rapid, fast-paced action experiences. But that’s what we do.
Now, let’s talk about psychedelics. I described to you a system where technology enables multimodal biosensing, so we can understand your state in real time. And I described us having the ability to change what you see, hear, smell, and feel. So we have the two sides. We have the ability to know what’s going on with you, and we have the ability to shape your environment. What we didn’t talk about is what you just said: creating a closed-loop psychedelic experience. That is the goal here. That we can have, let’s say a therapist, sitting in front of a patient or a participant in a research study, having access to this data. Maybe they have to, if you want to be science fiction here, picture them in virtual reality, watching a four-dimensional representation of your experience, of their patient’s experience, unfold to see, are they in high stress? Are they suffering now?
Okay, it’s okay for them to suffer, but only for 15 minutes. Because our data shows that after that, then it starts becoming more likely to cause harm than to help. So they’re watching this unfold and then they have these tools. They can say, “Oh, this is the time where it’s worth to move out of this high stress, deep internal attention, high arousal, high-awareness moment and bring it out.” And in order to do that, what I’m going to do is move them into a forest where they could smell pine, and hear a waterfall, and feel low frequency vibration across their body. And that will ease them out, and then we’ll have another day where we can go deep again. This is the closed loop, right?
We’re using real time data, and it can be done just with machine learning itself, and a processor or a human on board like I just described. That’s how we could create personalized experiences that are targeting those aspects of their brain function that need to be improved, whether they’re suffering and they have a pathology, or they’re just trying to enhance and elevate their minds.
Tim Ferriss: I’m just imagining an electro facilitator within some type of Minority Report, like virtual reality grabbing stimuli, adding them or subtracting them, combining them like the Swedish Chef adding ingredients. It’s quite a picture, it’s quite a picture.
Adam Gazzaley: Yeah, it is.
Tim Ferriss: And you say science fiction, but I think these things may end up being closer than people anticipate. Furthermore, I just want to say that the research you’ll be doing, the experimentation, brings up, and I find this tremendously exciting, so many challenging questions. I’m not going to say problems, but so many challenging questions. For instance, you just alluded to this, but when does it make sense to increase or expose someone to increased stress?
Speaking just N of 1, actually it’s more than N of 1 because I have friends who would share this opinion that many of — I’ll just speak for myself. Many of my most and positively impactful experiences with psychedelics that had positive, durable effects were very challenging experiences in safe environments. And so determining what the appropriate dose of distress is, if there is one, is such a fascinating question. Because there is a point where the dose makes the poison and all of a sudden someone comes out and they’re destabilized for two weeks —
Adam Gazzaley: Undoubtedly —
Tim Ferriss: Or potentially longer. So how do you thread that needle? It’s very hard to, even if — Sorry to —
Adam Gazzaley: No, please go —
Tim Ferriss: — but even if an experienced, say, indigenous healer could intuit that and do it effectively, while that is incredibly impressive, it does not increase the availability of psychedelics as a therapeutic tool, because that is a spider sense or some innate or trained ability that takes a very long time to develop.
Adam Gazzaley: Exactly.
Tim Ferriss: You can’t just copy and paste it. But if all of a sudden, like you said, you have this library of data, you have evidence to suggest where the tipping point is and when you should introduce that forest, I mean, the implications are really staggering.
Adam Gazzaley: Yeah. I won’t even repeat it. You said it perfectly, it would be silly. That is exactly what has excited me here. And then when I found out that those therapists and indigenous shaman, they were like, “Yeah, we would like to know that data too,” even the experts.
Now, what I’m really lit up by is talking to those individuals, allying with them. I’ve done this several times now, and it’s so much fun to say, “Okay, you’ve been doing this for 40 years. When you’re sitting in front of someone, how do you know if they’re suffering? And when do you decide to help them out, to lay hands on them or to introduce some scent?” Which is what they do. I’m taking notes. They’ll be like, “Well, I could see their face change.” I’m like, “Perfect. I could record facial expressions pretty easily with either camera and electrode.” They’ll be like, “Well, sometimes they vocalize. Also very, very accessible to us right now. And so that’s what’s really fun about designing these research studies, is not doing it from some academic halls and even resting on the scientific literature itself, because a lot of this is not recorded in papers, but it’s out there in the world, in true life, wisdom, and expertise that’s been accumulated over sometimes centuries, but finding those nuggets and then using the tools that I described and doing very carefully controlled research studies that would be accepted by even the most conservative of regulatory agencies or professionals out there to move this forward.
And as you said, to make it accessible. There is not nearly enough experts in the world for all the people in need. I mean, not even by an order of magnitude. So we have to figure this out, or this is just going to be a tool for the elite and just won’t have the access that we need it to.
Tim Ferriss: One thing I really appreciate about you is, with respect to this area, I wouldn’t say in particular, but it’s a good example. You’ve spent an incredible amount of time, and I know this because we’ve had so many conversations over the last few years, with practitioners who operate with different compounds in many different environments, with different populations in different geographies who have stylistically different approaches. And you have, as you mentioned, not sequestered yourself in this ivory tower of literature as your sole source of input. One challenge within the psychedelic community is that there’s no such thing as a psychedelic community. There are, in fact, what I would consider factions, in a sense. I mean, you have kind of the scientific group. Now, by scientific, let me qualify. You have scientists, people who are actually doing the work, you have well-educated folks who are secular, who succumb to a certain degree of scientism. I’m not sure what you would call it, but those who aren’t really scientifically literate, but view it dogmatically, almost like a religion.
Then you go all the way to the other side. You have people who might embrace indigenous traditions or some hybrid, say, neo-shamanic approach along the lines of — or Western psychotherapeutic approach along the lines of, say, a Leo Zeff or a Stan Grof. And there’s a lot of friction amongst these groups. I’m not surprised on one level because humans are humans and there’s a lot of tribal, I think, impulse readily available at any moment.
But to what would you attribute people thus far in your experience from these many different worlds, and there’s a whole spectrum being open and interested in the work that you’re doing. Because my experience has been that very often, the scientists don’t really want to embrace indigenous or facilitator wisdom and view it as hocus pocus, hand-wavy woo-woo, superstition. And then on the flip side, you have the people who are on, not necessarily indigenous side, I actually find a lot of the indigenous people who have a lineage of this, quite open-minded, but sort of in the neo-shamanic space are very dismissive of scientists and view it as overly reductionist and missing the point on some level. Long question, but why do you think people have responded so positively to you?
Adam Gazzaley: I think because at the fundamental level, everyone recognizes that this is experiential medicine, and that is how I start the conversation. I don’t know the best experience to lead to the best outcome. I’m not approaching this in a very rigid way of, “This is the approach that I think is going to lead to the best outcomes.” I’m just suggesting that thinking about this as a drug, from the point of view of molecule leads to effect, you take this antibiotic, the biote is killed, you’re better. That’s not what we’re talking about here. We’re talking about the creation of an experience that is undoubtedly induced or accelerated or enhanced by these compounds, but the nature of the experience leading to outcomes, I think everyone agrees upon that basic framework. So if you enter the conversation with that as the ground truth, I think that there is a lot more likelihood of reaching at least a commonality of view. Don’t we want to understand the experience more? Don’t we want to be able to guide?
Some of it is just language, like the word “control,” which we use in science all the time, is not a particularly warm word when it comes to a person’s life who’s suffering. So, yes. Okay. The word “guide” is a lot more favorable. Now we sort of, many times, not all times, talking about similar things there. We’re not talking about pushing you into this place. We’re talking about presenting you with options to enter this place. So some of it is just being really very careful about language, understanding the person’s perspective that you’re talking to, being respectful of the amount of time and expertise they have. And then just returning to the ground truth that this is an experiential medicine and there’s so much more we could learn in order to help more people. And that is where I find that there’s a great commonality.
Tim Ferriss: Well, Adam, I couldn’t be more excited. I’m going to ask you in a minute what the future looks like and how people can help, certainly, and where they can find you. I have those notes in front of me, not that you would need me to remind you of your own URLs.
But before we sort of wind to a close for this conversation, is there anything else that you would like to say to my audience, to request of listeners, a question you would like to pose? Anything at all that you would like to say before we get to the question of next steps and how people can help if they would like to help?
Adam Gazzaley: Yeah. I mean, just at a high level, I would just like to remind everyone that to keep an open mind. You might’ve heard things that we’ve talked about that are completely in your wheelhouse, that you’re just so fired up, like “That’s exactly what I love!” And others that might feel threatened by it or that it’s distorting the real value of these medicines. But I just encourage you to keep an open mind and realize that the underlying goal here is that there is so much suffering in the world. And we have done such an atrocious job of addressing that. If you look across the fields of cardiac health and infectious disease, despite the fact that we’re in a pandemic now, we’ve done so much better than we have in terms of mental suffering. And the idea that there’s a magic brain pill out there that’s going to fix it, it’s just not going to happen. It’s not true of these compounds either. We have to be really creative in how we think about treatments and how we use science and technology to get there. I just encourage people to keep an open mind. You don’t have to agree with everything you’ve heard, but the need is great and the opportunity is is here now. So I thank you for your patience in listening and going on this journey with Tim and I.
Tim Ferriss: Neuroscape.ucsf.edu. Just to reiterate, I’m so optimistic about this new chapter within Neuroscape and for you also. I mean, this is a big commitment for you, for a multitude of reasons. And I think a lot of people will be similarly excited and galvanized by this because you have UCSF, which is, from a science medicine research perspective, as blue chip as it comes. It is not an institution that has been heavily associated with psychedelics in any way previously. Your lab has also not been associated with psychedelics previously. And I think that it will hopefully inspire many people to take a close look at these tools, these medicines, and research associated with it. I think it’s going to be incredibly validating for the space and for that, I’m incredibly grateful.
How can people help? What are some of the next steps? Are you looking for financial support? What are you looking to do and what you need to do it?
Adam Gazzaley: Yeah. We need a lot of help. It takes a village and we have great people on board already. Jenny Mitchell is leading a site for the MAPS trial at Neuroscape in our division right now. So we already have some early momentum. Robin, of course, is coming on board, and couldn’t be more excited by what he’s going to add to this. So we have a great team, and we have UCSF support, but we need a little bit more of everything.
There may be listeners that have experience with the perspective that I just shared in terms of the experiential, the set and setting, they might have it from personal experience, they might have it as a practitioner or as a scientist, from any viewpoint, I want to hear about it. We want to be informed, as we talked about, Tim, not just based upon a literature, but based upon all of this real world data that has accumulated over time. And so that is one need right there, just educate us.
Tim Ferriss: How would you like to hear about it? Is hitting you on Twitter? Is there an email that is not going to bury you forever?
Adam Gazzaley: Yeah. Well, on gazzaley.com there’s a contact site and that would be a great way and I’ll share it with my team. So yeah, we want to be educated and one of my tenants is not to just think that we know everything. And in this case, none of us do. No one. The contact information on there and the way to offer that perspective to us is open. We probably won’t be able to reply to everyone, but you will be heard and that information will be shared and it could help inspire research and our own perspectives.
Tim Ferriss: So website? Gazzaley.com, G-A-Z-Z-A-L-E-Y.com
Adam Gazzaley: Correct.
Tim Ferriss: Please continue.
Adam Gazzaley: Yep. The next is financial support. We have done well, we have over $6 million in funding, which is enough to get Robin here and support it and to build out a first set of studies and to hire some great postdocs and bring on some junior faculty. But it doesn’t go that far when you’re talking about the type of division that I just described to you and the research objectives we have.
So there’s lots of opportunity. We want to build a new cutting edge facility at Neuroscape with multiple laboratories so that we can do more research, more rapidly. And so philanthropic support is always welcome at any level. And again, you can contact me through there, there’s also a contact on the Neuroscape site, if that’s more palatable to you. Whatever way you want to reach out and let us know if you would like to be part of the funding of this endeavor would be incredibly appreciated.
Tim Ferriss: Do you have a target raise amount that you’re able to disclose, or would you prefer not to have any specific number as a target?
Adam Gazzaley: When I first formulated this and then put the team together and we brainstormed about what we wanted to accomplish over the next five years in terms of building the team, in terms of having the research tools that we need, in terms of building the facilities, because we have space to actually create some new labs, very cutting edge labs, that bring this type of technology, but not in an intrusive way. To maintain the natural feel and the warmth, that’s tricky. So there’s design challenges. In order to accomplish that, our goal was $20 million. So we have a ways to go.
Now, adding $10 million right now would allow us to actually build the facility and that will unlock a massive amount. So that’s sort of what I’ve been keeping in my mind when I look towards what I hope that we’ll accomplish over the course of this year.
Tim Ferriss: Wonderful. And not to act as the pro bono development officer here, you have capable folks at UCSF for that, but I will just say for folks who may be wondering, I have some skin in the game here. I’m a big believer, huge believer in you, Adam, and Neuroscape, have been for a very long time. So I am also, through my foundation, contributing some capital, and I would imagine that people can donate appreciated securities, i.e. stocks, and possibly other things. Do you know if UCSF is able to receive cryptocurrencies of any type?
Adam Gazzaley: It’s a great question.
Tim Ferriss: Certainly, yeah.
Adam Gazzaley: I don’t know.
Tim Ferriss: This would be a good time to investigate that.
Adam Gazzaley: Yeah. That is a great, great question. And I will find out later today.
Tim Ferriss: Wonderful. I know that you and I have the mutual acquaintance of Rick Doblin. MAPS has in the past figured out ways to accept cryptocurrency. And in fact, some of their largest donations have come from Mr. Apple, maybe. Mr. Pineapple, as he is known through, I believe it was Bitcoin, but through cryptocurrency.
Adam Gazzaley: Interesting.
Tim Ferriss: So this would be good to investigate. And if you are able to do that, or if there is an approach to that, we put it in the show notes at tim.blog/podcast, for people who may be interested.
[THIS JUST IN: Breaking news. Yes, UCSF can now accept cryptocurrencies for Neuroscape and the work that Adam will be doing. I believe this could be a first for a major university. It’s a very big deal. And I’m supporting his work. If you would like to support his work through cryptocurrency, you can do that. And all you need to do it email email@example.com and they can provide you with instructions for how to do this. And now back to our conversation.]
Adam, I’m excited for you. I’m excited for the future of this field. I’m excited for your team. I’m excited for Robin and other people, not yet determined, who may contribute or join the team in some fashion. I really appreciate you taking the time to hop on the phone, especially looking like Old Man Time. You have a big beard. You have a big beard right now, which suits you. I like it. I like it. And for those who are wondering about the visual, Adam has been, I don’t know how long you’ve been the silver fox.
Adam Gazzaley: Since college.
Tim Ferriss: Since college. I mean, you look kind of like, I mean, not exactly, but like Storm from the X-Men. You have perfectly white hair, luscious locks of white hair, and now you have full head coverage with this incredible beard. It’s a great look. I like it.
Adam Gazzaley: Thanks, Tim. Tim, I just wanted to say before we jump off, thank you so much for your inspiration. Now you’re supporting this, your support over the years, not just financially, but in every way you’ve been a great friend and a great colleague to have on this journey. I’m buzzing right now at how much fun I had just going down memory lane and then looking to the future. I know your listeners already appreciate what you bring and I have my own perspective, being a longtime friend. And I just want to thank you for always giving all of my ideas an outlet and your attention, and then helping to share it with your listeners. So thank you so much.
Tim Ferriss: Well, thanks Adam. I love you and your family very much. I can’t wait to give you a proper hug in meatspace. This virtual shit is for the birds.
Adam Gazzaley: Yeah, I agree.
Tim Ferriss: We’ll get there eventually and hopefully in a few months, in fact. I can’t wait until we can actually break bread and have a drink together.
Adam Gazzaley: I look forward to that, too.
Tim Ferriss: Thanks, again, for taking the time and to everybody listening, this is exciting stuff. Check Adam out gazzaley.com, as mentioned, G-A-Z-Z-A-L-E-Y.com. Neuroscape, which honestly, even if you have zero interest in psychedelics, just for the other work that they’ve done, Neuroscape.ucsf.edu is well worth checking out. It is a glimpse of the future as far as I’m concerned. You can find him on Twitter @AdamGazz, G-A-Z-Z, which is also the handle on Instagram and Facebook.
We will have show notes for everything, including hopefully an update on whether or not Neuroscape and Adam can accept cryptocurrencies because Adam makes, and his team, make incredibly capital-efficient use of funds. They are like a lean, fast-growing, well-executed startup. That is part of the reason I’ve been so enthusiastically supportive, and I encourage people to take a look. So we’ll have links to everything at tim.blog/podcast. And thanks for tuning in.
The Tim Ferriss Show is one of the most popular podcasts in the world with more than 700 million downloads. It has been selected for "Best of Apple Podcasts" three times, it is often the #1 interview podcast across all of Apple Podcasts, and it's been ranked #1 out of 400,000+ podcasts on many occasions. To listen to any of the past episodes for free, check out this page.